title: Membranous nephropathy following intravitreal injection of bevacizumab.
authors.forename: Heino R
authors.initials: HR
authors.lastname: Anto
authors.forename: George F
authors.initials: GF
authors.lastname: Hyman
authors.forename: Jin Ping
authors.initials: JP
authors.lastname: Li
authors.forename: Samuel
authors.initials: S
authors.lastname: Spitalewitz
authors.forename: David
authors.initials: D
authors.lastname: Thomas
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D017809:Fatal Outcome; D015433:Glomerulonephritis, Membranous / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab